Clinical performance of the Solana® Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women

Charlotte A Gaydos, J. Schwebke, J. Dombrowski, J. Marrazzo, Jenell S. Coleman Fennell, B. Silver, M. Barnes, L. Crane, P. Fine

Research output: Contribution to journalArticle

Abstract

Background: Solana® (Quidel) is a new rapid (<40 min.) point-of-care (POC) test for qualitative detection of Trichomonas vaginalis (TV) DNA. The assay has two steps: 1) specimen preparation, and 2) amplification and detection using isothermal Helicase-Dependent Amplification (HDA). The objective was to demonstrate the performance of Solana for vaginal swabs and female urines based on comparison to wet mount and TV culture. Performance was also compared to the Aptima-TV assay. Methods: Urine and four clinician-collected vaginal swabs were collected. The first two were used for FDA composite reference (wet mount; InPouch TV Culture). The third swab was used for Solana. Sensitivity/specificity were based on the reference method. A specimen was considered positive if either test was positive. The fourth swab was for Aptima-TV. Results: Vaginal swabs and urines were obtained from 501 asymptomatic and 543 symptomatic women. Prevalence of TV by was 11.5%. For swabs, Solana® demonstrated high sensitivity and specificity from asymptomatic (100%/98.9%) and symptomatic (98.6%/98.5%) women, as well as for urines from asymptomatic (98.0%/98.4%) and symptomatic (92.9%/97.9%) women, compared to the reference method. Compared to Aptima-TV, the sensitivity/specificity was 89.7%/99.0% for swabs and 100%/98.9% for urines. Conclusion: The Solana® assay performed well compared to the reference assays.

Original languageEnglish (US)
Pages (from-to)303-306
Number of pages4
JournalExpert Review of Molecular Diagnostics
Volume17
Issue number3
DOIs
StatePublished - Mar 4 2017

Fingerprint

Point-of-Care Systems
Trichomonas
Trichomonas vaginalis
Urine
Sensitivity and Specificity
DNA

Keywords

  • point-of-care test
  • Solana
  • Trichomonas vaginalis
  • trichomoniasis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Clinical performance of the Solana® Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women. / Gaydos, Charlotte A; Schwebke, J.; Dombrowski, J.; Marrazzo, J.; Coleman Fennell, Jenell S.; Silver, B.; Barnes, M.; Crane, L.; Fine, P.

In: Expert Review of Molecular Diagnostics, Vol. 17, No. 3, 04.03.2017, p. 303-306.

Research output: Contribution to journalArticle

@article{6ed54382ead84d20ba8d441fdfc56a80,
title = "Clinical performance of the Solana{\circledR} Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women",
abstract = "Background: Solana{\circledR} (Quidel) is a new rapid (<40 min.) point-of-care (POC) test for qualitative detection of Trichomonas vaginalis (TV) DNA. The assay has two steps: 1) specimen preparation, and 2) amplification and detection using isothermal Helicase-Dependent Amplification (HDA). The objective was to demonstrate the performance of Solana for vaginal swabs and female urines based on comparison to wet mount and TV culture. Performance was also compared to the Aptima-TV assay. Methods: Urine and four clinician-collected vaginal swabs were collected. The first two were used for FDA composite reference (wet mount; InPouch TV Culture). The third swab was used for Solana. Sensitivity/specificity were based on the reference method. A specimen was considered positive if either test was positive. The fourth swab was for Aptima-TV. Results: Vaginal swabs and urines were obtained from 501 asymptomatic and 543 symptomatic women. Prevalence of TV by was 11.5{\%}. For swabs, Solana{\circledR} demonstrated high sensitivity and specificity from asymptomatic (100{\%}/98.9{\%}) and symptomatic (98.6{\%}/98.5{\%}) women, as well as for urines from asymptomatic (98.0{\%}/98.4{\%}) and symptomatic (92.9{\%}/97.9{\%}) women, compared to the reference method. Compared to Aptima-TV, the sensitivity/specificity was 89.7{\%}/99.0{\%} for swabs and 100{\%}/98.9{\%} for urines. Conclusion: The Solana{\circledR} assay performed well compared to the reference assays.",
keywords = "point-of-care test, Solana, Trichomonas vaginalis, trichomoniasis",
author = "Gaydos, {Charlotte A} and J. Schwebke and J. Dombrowski and J. Marrazzo and {Coleman Fennell}, {Jenell S.} and B. Silver and M. Barnes and L. Crane and P. Fine",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/14737159.2017.1282823",
language = "English (US)",
volume = "17",
pages = "303--306",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Clinical performance of the Solana® Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women

AU - Gaydos, Charlotte A

AU - Schwebke, J.

AU - Dombrowski, J.

AU - Marrazzo, J.

AU - Coleman Fennell, Jenell S.

AU - Silver, B.

AU - Barnes, M.

AU - Crane, L.

AU - Fine, P.

PY - 2017/3/4

Y1 - 2017/3/4

N2 - Background: Solana® (Quidel) is a new rapid (<40 min.) point-of-care (POC) test for qualitative detection of Trichomonas vaginalis (TV) DNA. The assay has two steps: 1) specimen preparation, and 2) amplification and detection using isothermal Helicase-Dependent Amplification (HDA). The objective was to demonstrate the performance of Solana for vaginal swabs and female urines based on comparison to wet mount and TV culture. Performance was also compared to the Aptima-TV assay. Methods: Urine and four clinician-collected vaginal swabs were collected. The first two were used for FDA composite reference (wet mount; InPouch TV Culture). The third swab was used for Solana. Sensitivity/specificity were based on the reference method. A specimen was considered positive if either test was positive. The fourth swab was for Aptima-TV. Results: Vaginal swabs and urines were obtained from 501 asymptomatic and 543 symptomatic women. Prevalence of TV by was 11.5%. For swabs, Solana® demonstrated high sensitivity and specificity from asymptomatic (100%/98.9%) and symptomatic (98.6%/98.5%) women, as well as for urines from asymptomatic (98.0%/98.4%) and symptomatic (92.9%/97.9%) women, compared to the reference method. Compared to Aptima-TV, the sensitivity/specificity was 89.7%/99.0% for swabs and 100%/98.9% for urines. Conclusion: The Solana® assay performed well compared to the reference assays.

AB - Background: Solana® (Quidel) is a new rapid (<40 min.) point-of-care (POC) test for qualitative detection of Trichomonas vaginalis (TV) DNA. The assay has two steps: 1) specimen preparation, and 2) amplification and detection using isothermal Helicase-Dependent Amplification (HDA). The objective was to demonstrate the performance of Solana for vaginal swabs and female urines based on comparison to wet mount and TV culture. Performance was also compared to the Aptima-TV assay. Methods: Urine and four clinician-collected vaginal swabs were collected. The first two were used for FDA composite reference (wet mount; InPouch TV Culture). The third swab was used for Solana. Sensitivity/specificity were based on the reference method. A specimen was considered positive if either test was positive. The fourth swab was for Aptima-TV. Results: Vaginal swabs and urines were obtained from 501 asymptomatic and 543 symptomatic women. Prevalence of TV by was 11.5%. For swabs, Solana® demonstrated high sensitivity and specificity from asymptomatic (100%/98.9%) and symptomatic (98.6%/98.5%) women, as well as for urines from asymptomatic (98.0%/98.4%) and symptomatic (92.9%/97.9%) women, compared to the reference method. Compared to Aptima-TV, the sensitivity/specificity was 89.7%/99.0% for swabs and 100%/98.9% for urines. Conclusion: The Solana® assay performed well compared to the reference assays.

KW - point-of-care test

KW - Solana

KW - Trichomonas vaginalis

KW - trichomoniasis

UR - http://www.scopus.com/inward/record.url?scp=85011009047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011009047&partnerID=8YFLogxK

U2 - 10.1080/14737159.2017.1282823

DO - 10.1080/14737159.2017.1282823

M3 - Article

VL - 17

SP - 303

EP - 306

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 3

ER -